BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC Scientific Document Group . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 2021:zwab154. [PMID: 34558602 DOI: 10.1093/eurjpc/zwab154] [Cited by in Crossref: 40] [Cited by in F6Publishing: 54] [Article Influence: 40.0] [Reference Citation Analysis]
Number Citing Articles
1 Jha KK, Adhikari R, Tasdighi E, Osuji N, Rajan T, Blaha MJ. Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes. Curr Atheroscler Rep 2022. [DOI: 10.1007/s11883-022-01066-y] [Reference Citation Analysis]
2 Karlsen HR, Langvik E. Sex-specific psychological risk profiles of CVD in the HUNT study: the role of neuroticism and extraversion. Psychology & Health 2022. [DOI: 10.1080/08870446.2022.2146113] [Reference Citation Analysis]
3 Saiz LC, Gorricho J, Garjón J, Celaya MC, Erviti J, Leache L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd010315.pub5] [Reference Citation Analysis]
4 Ma J, Zhang H, Chen Y, Liu X, Tian J, Shen W. The Role of Macrophage Iron Overload and Ferroptosis in Atherosclerosis. Biomolecules 2022;12:1702. [DOI: 10.3390/biom12111702] [Reference Citation Analysis]
5 Halasz G, Piepoli MF. Editorial comments: Focus on cardiovascular risk screening. European Journal of Preventive Cardiology 2022;29:2073-2075. [DOI: 10.1093/eurjpc/zwac247] [Reference Citation Analysis]
6 Sartoretti E, Gennari AG, Maurer A, Sartoretti T, Skawran S, Schwyzer M, Rossi A, Giannopoulos AA, Buechel RR, Gebhard C, Huellner MW, Messerli M. Opportunistic deep learning powered calcium scoring in oncologic patients with very high coronary artery calcium (≥ 1000) undergoing 18F-FDG PET/CT. Sci Rep 2022;12:19191. [DOI: 10.1038/s41598-022-20005-0] [Reference Citation Analysis]
7 Masson W, Barbagelata L, Falconi M, Arenaza DPD. Association between physical activity and coronary artery calcification estimated by computed tomography: A systematic review. Clínica e Investigación en Arteriosclerosis 2022. [DOI: 10.1016/j.arteri.2022.10.001] [Reference Citation Analysis]
8 Wang K, Wang R, Yang J, Liu X, Shen H, Sun Y, Zhou Y, Fang Z, Ge H. Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment. Front Cardiovasc Med 2022;9:913869. [DOI: 10.3389/fcvm.2022.913869] [Reference Citation Analysis]
9 Subirana I, Camps-Vilaró A, Elosua R, Marrugat J, Tizón-Marcos H, Palomo I, Dégano IR. Cholesterol and Hypertension Treatment Improve Coronary Risk Prediction but Not Time-Dependent Covariates or Competing Risks. Clin Epidemiol 2022;14:1145-54. [PMID: 36254303 DOI: 10.2147/CLEP.S374581] [Reference Citation Analysis]
10 Ortiz A, Wanner C, Gansevoort R, Ortiz A, Wanner C, Gansevoort RT, Cozzolino M, Fliser D, Gambaro G, Ong A, Rosenkranz AR, Rychlık I, Sarafidis P, Torra R, Tuglular S; the ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Clinical Kidney Journal 2022. [DOI: 10.1093/ckj/sfac199] [Reference Citation Analysis]
11 Ortiz A, Wanner C, Gansevoort R; ERA Council . Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Nephrol Dial Transplant 2022:gfac257. [PMID: 36216362 DOI: 10.1093/ndt/gfac257] [Reference Citation Analysis]
12 Dulin AJ, Park JW, Scarpaci MM, Dionne LA, Sims M, Needham BL, Fava JL, Eaton CB, Kanaya AM, Kandula NR, Loucks EB, Howe CJ. Examining relationships between perceived neighborhood social cohesion and ideal cardiovascular health and whether psychosocial stressors modify observed relationships among JHS, MESA, and MASALA participants. BMC Public Health 2022;22:1890. [PMID: 36221065 DOI: 10.1186/s12889-022-14270-x] [Reference Citation Analysis]
13 Miglinas M, Ševčenko V, Račaitė A, Žakauskienė U, Vickienė A, Miglinė V, Wang W, Beaney T, Poulter NR, Macioniene E. May Measurement Month 2017-2019: an analysis of blood pressure screening results from Lithuania. Eur Heart J Suppl 2022;24:F22-4. [PMID: 36225270 DOI: 10.1093/eurheartjsupp/suac043] [Reference Citation Analysis]
14 Melaika K, Sveikata L, Vilionskis A, Wiśniewski A, Jurjans K, Klimašauskas A, Jatužis D, Masiliūnas R. Prehospital Stroke Care, Paramedic Training Needs, and Hospital-Directed Feedback in Lithuania. Healthcare (Basel) 2022;10:1958. [PMID: 36292405 DOI: 10.3390/healthcare10101958] [Reference Citation Analysis]
15 Kotlyarov S, Kotlyarova A. Clinical significance of polyunsaturated fatty acids in the prevention of cardiovascular diseases. Front Nutr 2022;9:998291. [PMID: 36276836 DOI: 10.3389/fnut.2022.998291] [Reference Citation Analysis]
16 Merino J. A Reassessment of the Causal Effects of Dysglycemia on Atherosclerotic and Thrombotic Events. Diabetes 2022;71:2075-7. [PMID: 36126207 DOI: 10.2337/dbi22-0012] [Reference Citation Analysis]
17 Izar MC, Fonseca FAH. Blood Pressure Variability and Cardiovascular Risk in ELSA-Brasil: A Potential Surrogate Marker for Predicting Mortality and Cardiovascular Outcomes? Arq Bras Cardiol 2022;119:512-3. [PMID: 36287406 DOI: 10.36660/abc.20220525] [Reference Citation Analysis]
18 Kunimura A, Miura K, Segawa H, Torii S, Kondo K, Hisamatsu T, Kadota A, Fujiyoshi A, Yano Y, Nakagawa Y, Okamura T, Ueshima H; SESSA research group. Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men. J Atheroscler Thromb 2022. [PMID: 36123046 DOI: 10.5551/jat.63549] [Reference Citation Analysis]
19 Tunheim K, Dammen T, Baardstu S, Moum T, Munkhaugen J, Papageorgiou C. Relationships between depression, anxiety, type D personality, and worry and rumination in patients with coronary heart disease. Front Psychol 2022;13:929410. [DOI: 10.3389/fpsyg.2022.929410] [Reference Citation Analysis]
20 Toussirot E, Gallais-sérézal I, Aubin F. The cardiometabolic conditions of psoriatic disease. Front Immunol 2022;13:970371. [DOI: 10.3389/fimmu.2022.970371] [Reference Citation Analysis]
21 Campello E, Prandoni P. Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review. Semin Thromb Hemost 2022. [PMID: 36063847 DOI: 10.1055/s-0042-1757133] [Reference Citation Analysis]
22 Campello E, Prandoni P. Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review. Semin Thromb Hemost 2022. [PMID: 36055262 DOI: 10.1055/s-0042-1753527] [Reference Citation Analysis]
23 Wolf S, Spirk D, Forgo G, Sebastian T, Voci D, Kucher N, Barco S. Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty. Vasa 2022. [DOI: 10.1024/0301-1526/a001025] [Reference Citation Analysis]
24 Qian J, Li Z, Zhang X, Chen J, Ding C, Yang P, Liu Y, Shi M, Ren X, Ge J. Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-Dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-Controlled Study in Chinese Patients. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2022.08.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kiedrowicz M, Duchnik E, Wesołowska J, Bania B, Peregud-pogorzelska M, Maciejewska-markiewicz D, Stachowska E, Kruk J, Marchlewicz M. Early and Long-Term Effects of Abdominal Fat Reduction Using Ultrasound and Radiofrequency Treatments. Nutrients 2022;14:3498. [DOI: 10.3390/nu14173498] [Reference Citation Analysis]
26 . Childhood Risk Factors and Adult Cardiovascular Events. N Engl J Med 2022;387:472-4. [DOI: 10.1056/nejmc2208135] [Reference Citation Analysis]
27 Maștaleru A, Cojocariu AS, Oancea A, Leon-constantin M, Roca M, Zota IM, Abdulan IM, Rusu C, Trandafir LM, Costache AD, Cojocaru E, Roca IC, Mitu F. Eating Habits in Patients with Familial Hypercholesterolemia from North-Eastern Romania. Nutrients 2022;14:3124. [DOI: 10.3390/nu14153124] [Reference Citation Analysis]
28 Essien UR, Tang Y, Figueroa JF, Litam TMA, Tang F, Jones PG, Patel R, Wadhera RK, Desai NR, Mehta SN, Kosiborod MN, Vaduganathan M. Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry. Diabetes Care 2022;45:1549-57. [PMID: 35796766 DOI: 10.2337/dc21-1178] [Reference Citation Analysis]
29 Yang L, Xiao YY, Shao L, Ouyang CS, Hu Y, Li B, Lei LF, Wang H. Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization: A case report. World J Clin Cases 2022; 10(19): 6728-6735 [DOI: 10.12998/wjcc.v10.i19.6728] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Barbagelata L, Masson W, Rossi E, Lee M, Lagoria J, Vilas M, Pizarro R, Rosa Diez G. Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies. High Blood Press Cardiovasc Prev 2022. [PMID: 35751783 DOI: 10.1007/s40292-022-00531-8] [Reference Citation Analysis]
31 Svendsen ML, Gadager BB, Stapelfeldt CM, Ravn MB, Palner SM, Maribo T. To what extend is socioeconomic status associated with not taking up and dropout from cardiac rehabilitation: a population-based follow-up study. BMJ Open 2022;12:e060924. [PMID: 35728905 DOI: 10.1136/bmjopen-2022-060924] [Reference Citation Analysis]
32 De Backer G. Towards more personalized low-density lipoprotein-cholesterol lowering strategies in patients with atherosclerotic cardiovascular disease. Eur J Prev Cardiol 2022:zwac111. [PMID: 35655392 DOI: 10.1093/eurjpc/zwac111] [Reference Citation Analysis]
33 Daugaard C, Iversen L, Hjuler KF. Comorbidity in Adult Psoriasis: Considerations for the Clinician. PTT 2022;Volume 12:139-150. [DOI: 10.2147/ptt.s328572] [Reference Citation Analysis]
34 Sadowski K, Piotrowicz R, Kłopotowski M, Wolszakiewicz J, Lech A, Witkowski A, Smolis-bąk E, Kowalik I, Mierzyńska A, Piotrowska D, Dobrowolski P, Dąbrowski M, Sadowy E, Piotrowicz E. Efficacy and Safety of Hybrid Cardiac Telerehabilitation in Patients with Hypertrophic Cardiomyopathy without Left Ventricular Outflow Tract Obstruction and Preserved Ejection Fraction—A Study Design. Applied Sciences 2022;12:5046. [DOI: 10.3390/app12105046] [Reference Citation Analysis]
35 Szyszkowska A, Barańska S, Sawicki R, Tarasiuk E, Dubatówka M, Kondraciuk M, Sawicka-śmiarowska E, Knapp M, Głowiński J, Kamiński K, Lisowska A. Insulin-Like Growth Factor-Binding Protein 7 (IGFBP-7)—New Diagnostic and Prognostic Marker in Symptomatic Peripheral Arterial Disease?—Pilot Study. Biomolecules 2022;12:712. [DOI: 10.3390/biom12050712] [Reference Citation Analysis]
36 Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Curr Atheroscler Rep 2022. [PMID: 35507279 DOI: 10.1007/s11883-022-01028-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Danese M, Sidelnikov E, Villa G, Catterick D, Iqbal M, Gleeson M, Lubeck D, Patel J. Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK. BMJ Open 2022;12:e055015. [PMID: 35487737 DOI: 10.1136/bmjopen-2021-055015] [Reference Citation Analysis]
38 Li N, Zhang J, Xu Y, Yu M, Zhou G, Zheng Y, Zhou E, He W, Sun W, Xu L, Zhang L. A Novel Nomogram Based on a Competing Risk Model Predicting Cardiovascular Death Risk in Patients With Chronic Kidney Disease. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.827988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Gili S, Giuliani M, Santagostino Baldi G, Teruzzi G, Pravettoni G, Montorsi P, Trabattoni D. Early Detection of Cardiovascular Risk Factors and Definition of Psychosocial Profile in Women Through a Systematic Approach: The Monzino Women Heart Center's Experience. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.844563] [Reference Citation Analysis]
40 Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, Chernyak N, Icks A, Kelm M, Brockmeyer M, Wolff G. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ Open 2022;12:e048893. [PMID: 35210334 DOI: 10.1136/bmjopen-2021-048893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch‐ernst KI, Knutsen HK, Maciuk A, Mangelsdorf I, Mcardle HJ, Naska A, Peláez C, Pentieva K, Siani A, Thies F, Tsabouri S, Adan R, Emmett P, Galli C, Kersting M, Moynihan P, Tappy L, Ciccolallo L, de Sesmaisons‐lecarré A, Fabiani L, Horvath Z, Martino L, Muñoz Guajardo I, Valtueña Martínez S, Vinceti M; EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Tolerable upper intake level for dietary sugars. EFS2 2022;20. [DOI: 10.2903/j.efsa.2022.7074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
42 Mengozzi A, Virdis A. Uric acid and cardiovascular risk stratification in the acute coronary syndromes: a friend we should mind. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.02.017] [Reference Citation Analysis]
43 Halasz G, Parati G, Piepoli MF. Editor comment: Focus on cardiovascular prevention. Eur J Prev Cardiol 2021;28:1523-5. [PMID: 34929043 DOI: 10.1093/eurjpc/zwab194] [Reference Citation Analysis]
44 Ferraz-Amaro I, Corrales A, Atienza-Mateo B, Vegas-Revenga N, Prieto-Peña D, Sánchez-Martín J, Almeida C, Quevedo-Abeledo JC, Blanco R, González-Gay MÁ. SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Diagnostics (Basel) 2021;11:2363. [PMID: 34943599 DOI: 10.3390/diagnostics11122363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Friebel J, Moritz E, Witkowski M, Jakobs K, Strässler E, Dörner A, Steffens D, Puccini M, Lammel S, Glauben R, Nowak F, Kränkel N, Haghikia A, Moos V, Schutheiss HP, Felix SB, Landmesser U, Rauch BH, Rauch U. Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation. Cells 2021;10:3517. [PMID: 34944024 DOI: 10.3390/cells10123517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]